Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Market Status
  5. Rd
  6. Phase Iii

Phase III

Evaluate

Thumbnail
March 23, 2023

Dupixent pushes towards a big new use

Thumbnail
March 22, 2023

Second pivotal hit brings Claudin18.2 closer to approval

Article image
Vantage logo
March 20, 2023

AAD 2023 – UCB and Acelyrin take aim at hidradenitis suppurativa

But Humira remains the one to beat.

Article image
Vantage logo
March 13, 2023

Calliditas sets the bar for its kidney disease rivals

Article image
Vantage logo
March 06, 2023

ACC 2023 – Merck reaches for the stars

The Stellar trial of sotatercept lives up to its name, but the asset did not come cheap.

Article image
Vantage logo
February 17, 2023

Moderna’s post-Covid prospects dim

Article image
Vantage logo
February 16, 2023

Sanofi and Regeneron face a high-risk test for Dupixent

A pivotal readout approaches in COPD, where other biologicals have fallen short.

Article image
Vantage logo
February 15, 2023

Spotlight – still plenty of hopefuls in lung fibrosis

Roche’s zinpentraxin alfa is out of the running, but Bristol, Blade, Pliant and others have contenders in the mid-stage idiopathic pulmonary fibrosis pipeline.

Article image
Vantage logo
February 14, 2023

The next big tests for Argenx and its followers

Some believe that blocking FcRn has TNF-like potential, and J&J, Immunovant and UCB are all hot on Argenx’s heels.

Article image
Vantage logo
February 09, 2023

Galapagos’s losing streak with Jyseleca continues

Article image
Vantage logo
February 08, 2023

Biohaven looks to seize a new opportunity

The post-Pfizer pipeline looks disparate, but the group insists there is a method to its fast-follower approach.

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 17, 2023

PD(L)anner – February 2023

February 09, 2023

Biopharma and Medtech Review 2022

View more...

Editor's Picks

Vantage logo
March 13, 2023

Silicon Valley Bank: biopharma’s latest crisis

Vantage logo
March 13, 2023

Pfizer rescues biotech

Vantage logo
February 28, 2023

Why Pfizer (and others) will be interested in Seagen

Vantage logo
March 04, 2023

ACC 2023 – Esperion’s outcomes win looks lacklustre

Vantage logo
March 06, 2023

T-cell receptor behemoths consolidate? Not quite

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up